OBJECTIVES: Crohn’s disease (CD) is a chronic inflammatory disease that is not curable at the moment. This study provides information on the current supply with biological agents and its related costs in Germany. METHODS: A retrospective claims data analysis was conducted utilizing the Institute for Applied Health Research (InGef) Berlin, formerly HRI Health Risk Institute, database including approximately 6.7 million insured anonymities originating from 63 statutory health insurances in Germany. Analyses were performed by the InGef institute. A sample with approximately 4 million insured persons was drawn and stratified by age and gender according to the official demographic structure of the German statutory health insured population (DeStatis, Dec 31^st, 2013). Patient data from 2012 - 2016 were included if they met the following conditions: Main diagnosis of CD (ICD-10 code K50.-), and start / maintenance / switch of treatment with CD approved biological agent(s) (at least for three months). The study evaluated hospital admission, change in medication and direct medical costs (drug, outpatient care, hospitalization). RESULTS: Leading biological agents for 1^st line treatment of CD are adalimumab and infliximab, however, at a low level of share of prescriptions. Both agents are administered mostly to patients already on treatment (in 2015 adalimumab 57.6 % vs. infliximab 39.9 %). The total costs of the included 1’721 patients add up to € 38’572’694 in 2015. Total number of patients, number of hospital admissions and total treatment costs including all individual cost items (costs of biological agents / other medication / outpatient care / hospitalizations) grew yearly on average between 5.0 % and 21.8 % (2012 – 2015). CONCLUSIONS: Adalimumab and infliximab are those biological agents mainly used for treating MC. All cost items grew steadily over the last 4 years. Total costs in 2015 were € 38.6 million (on average € 22’413 per patient).